Literature DB >> 25991487

Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients.

Sree Harsha Tirumani1,2, Atul B Shinagare3,4, Ailbhe C O'Neill4, Mizuki Nishino3,4, Michael H Rosenthal3,4, Nikhil H Ramaiya3,4.   

Abstract

OBJECTIVES: To validate estimated tumour volumetry in primary gastric gastrointestinal stromal tumours (GISTs) using semiautomated volumetry.
METHODS: In this IRB-approved retrospective study, we measured the three longest diameters in x, y, z axes on CTs of primary gastric GISTs in 127 consecutive patients (52 women, 75 men, mean age 61 years) at our institute between 2000 and 2013. Segmented volumes (Vsegmented) were obtained using commercial software by two radiologists. Estimate volumes (V1-V6) were obtained using formulae for spheres and ellipsoids. Intra- and interobserver agreement of Vsegmented and agreement of V1-6 with Vsegmented were analysed with concordance correlation coefficients (CCC) and Bland-Altman plots.
RESULTS: Median Vsegmented and V1-V6 were 75.9, 124.9, 111.6, 94.0, 94.4, 61.7 and 80.3 cm(3), respectively. There was strong intra- and interobserver agreement for Vsegmented. Agreement with Vsegmented was highest for V6 (scalene ellipsoid, x ≠ y ≠ z), with CCC of 0.96 [95 % CI 0.95-0.97]. Mean relative difference was smallest for V6 (0.6 %), while it was -19.1 % for V5, +14.5 % for V4, +17.9 % for V3, +32.6 % for V2 and +47 % for V1.
CONCLUSION: Ellipsoidal approximations of volume using three measured axes may be used to closely estimate Vsegmented when semiautomated techniques are unavailable. KEY POINTS: Estimation of tumour volume in primary GIST using mathematical formulae is feasible. Gastric GISTs are rarely spherical. Segmented volumes are highly concordant with three axis-based scalene ellipsoid volumes. Ellipsoid volume can be used as an alternative for automated tumour volumetry.

Entities:  

Keywords:  Ellipsoid; Estimated volumtery; Gastrointestinal stromal tumour; RECIST; Sphere

Mesh:

Year:  2015        PMID: 25991487      PMCID: PMC4654722          DOI: 10.1007/s00330-015-3829-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  34 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.

Authors:  Mizuki Nishino; Mengye Guo; David M Jackman; Pamela J DiPiro; Jeffrey T Yap; Tak K Ho; Hiroto Hatabu; Pasi A Jänne; Annick D Van den Abbeele; Bruce E Johnson
Journal:  Acad Radiol       Date:  2010-10-30       Impact factor: 3.173

3.  Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.

Authors:  Markku Miettinen; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

4.  A concordance correlation coefficient to evaluate reproducibility.

Authors:  L I Lin
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

6.  Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer.

Authors:  P David Mozley; Claus Bendtsen; Binsheng Zhao; Lawrence H Schwartz; Matthias Thorn; Yuanxin Rong; Luduan Zhang; Andrea Perrone; René Korn; Andrew J Buckler
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

7.  Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

Authors:  Dian Wang; Qiang Zhang; Charles D Blanke; George D Demetri; Michael C Heinrich; James C Watson; John P Hoffman; Scott Okuno; John M Kane; Margaret von Mehren; Burton L Eisenberg
Journal:  Ann Surg Oncol       Date:  2011-12-28       Impact factor: 5.344

8.  MRI and Diffusion-weighted MRI Volumetry for Identification of Complete Tumor Responders After Preoperative Chemoradiotherapy in Patients With Rectal Cancer: A Bi-institutional Validation Study.

Authors:  Doenja M J Lambregts; Sheng-Xiang Rao; Sander Sassen; Milou H Martens; Luc A Heijnen; Jeroen Buijsen; Meindert Sosef; Geerard L Beets; Roy A Vliegen; Regina G H Beets-Tan
Journal:  Ann Surg       Date:  2015-12       Impact factor: 12.969

9.  Tumor volume reduction assessed by planning computed tomography in patients with rectal cancer during preoperative chemoradiation: impact of residual tumor volume on the prediction of pathologic tumor regression.

Authors:  Jung Ae Lee; DaeSik Yang; Won Sup Yoon; Young Je Park; Chul Yong Kim; Hong-Young Moon; Sun-Il Lee
Journal:  Tumori       Date:  2014 Mar-Apr

10.  Tumor volume as an alternative response measurement for imatinib treated GIST patients.

Authors:  Gaia Schiavon; Alessandro Ruggiero; Patrick Schöffski; Bronno van der Holt; Dave J Bekers; Karel Eechoute; Vincent Vandecaveye; Gabriel P Krestin; Jaap Verweij; Stefan Sleijfer; Ron H J Mathijssen
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

View more
  9 in total

1.  Computed tomography features and predictive findings of ruptured gastrointestinal stromal tumours.

Authors:  Jin Sil Kim; Hyun Jin Kim; Seong Ho Park; Jong Seok Lee; Ah Young Kim; Hyun Kwon Ha
Journal:  Eur Radiol       Date:  2016-10-19       Impact factor: 5.315

2.  Predictive features of CT for risk stratifications in patients with primary gastrointestinal stromal tumour.

Authors:  Cuiping Zhou; Xiaohui Duan; Xiang Zhang; Huijun Hu; Dongye Wang; Jun Shen
Journal:  Eur Radiol       Date:  2015-12-23       Impact factor: 5.315

3.  Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay.

Authors:  David Hsiehchen; Magdalena Espinoza; David E Gerber; Muhammad S Beg
Journal:  Cancer Biol Ther       Date:  2021-08-14       Impact factor: 4.875

4.  [Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis].

Authors:  S C Brandelik; J Krzykalla; T Hielscher; J Hillengass; J K Kloth; H U Kauczor; M A Weber
Journal:  Radiologe       Date:  2018-01       Impact factor: 0.635

5.  Gastrointestinal Stromal Tumors Risk of Recurrence Stratification by Tumor Volume is a Best Predictor Compared with Risk Based on Mitosis and Tumor Size.

Authors:  Leonardo S Lino-Silva; Patricia Segales-Rojas; Eduardo Aguilar-Cruz; Rosa A Salcedo-Hernández; César Zepeda-Najar
Journal:  J Gastrointest Cancer       Date:  2019-09

6.  Predictors of hearing functional outcome following surgery for cerebellopontine angle meningioma.

Authors:  Nida Fatima; Anne K Maxwell; Anna La Dine; Zachary R Barnard; Gautam U Mehta; Eric P Wilkinson; Derald E Brackmann; William H Slattery; Gregory P Lekovic
Journal:  J Neurooncol       Date:  2022-02-03       Impact factor: 4.130

Review 7.  Update on Gastrointestinal Stromal Tumors for Radiologists.

Authors:  Sree Harsha Tirumani; Akshay D Baheti; Harika Tirumani; Ailbhe O'Neill; Jyothi P Jagannathan
Journal:  Korean J Radiol       Date:  2017-01-05       Impact factor: 3.500

8.  Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinib-Treated Patients With Gastrointestinal Stromal Tumors.

Authors:  E Schindler; S M Krishnan; Rhj Mathijssen; A Ruggiero; G Schiavon; L E Friberg
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-05-30

9.  Predicting Chemotherapeutic Response for Far-advanced Gastric Cancer by Radiomics with Deep Learning Semi-automatic Segmentation.

Authors:  Jing-Wen Tan; Lan Wang; Yong Chen; WenQi Xi; Jun Ji; Lingyun Wang; Xin Xu; Long-Kuan Zou; Jian-Xing Feng; Jun Zhang; Huan Zhang
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.